The (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses: Fact or Fallacy?

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.13, Iss.4, 1998-04, pp. : 389-396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-benefit or cost-utility analysis?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?

By Shantsila Eduard Watson Timothy Lip Gregory Y.H.

PharmacoEconomics, Vol. 24, Iss. 10, 2006-01 ,pp. : 1035-1038

Adis International

Access to resources Recommend Favorite

Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level?

By Bala M.V.

PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. : 495-498

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness League Tables: Valuable Guidance for Decision Makers?

By Mauskopf J.

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 991-1000

Adis International

Access to resources Recommend Favorite